We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
126
Fate Therapeutics
FATE
$322M
$5.77M 0.13%
+70,000
New +$6.71M
CNST
127
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$5.43M 0.12%
232,000
-743
-0.3% -$22.5K
DXCM icon
128
DexCom
DXCM
$33.1B
$5.39M 0.12%
+60,000
New +$5.63M
PHAS
129
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.38M 0.12%
1,553,974
+239,600
+18% +$972K
GRTX
130
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.01M 0.11%
568,252
+700
+0.1% +$7.68K
NUVB icon
131
Nuvation Bio
NUVB
$2.32B
$4.2M 0.09%
+402,088
New +$4.5M
RPRX icon
132
Royalty Pharma
RPRX
$25.8B
$3.49M 0.08%
80,000
-400,000
-83% -$19M
BLSA
133
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.27M 0.07%
309,000
– –
PSTX
134
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.77M 0.06%
289,754
– –
CNTB
135
Connect Biopharma Holdings
CNTB
$135M
$2.2M 0.05%
+119,114
New +$2.03M
SNCE
136
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.09M 0.05%
10,310
– –
PRDS
137
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.08M 0.05%
+209,332
New +$2.16M
EUCRU
138
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.06M 0.05%
206,000
– –
TMPMU
139
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.06M 0.04%
206,000
– –
JYAC
140
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.03M 0.04%
206,200
– –
PHICU
141
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$2.02M 0.04%
201,044
– –
MLTX icon
142
MoonLake Immunotherapeutics
MLTX
$1.47B
$1.58M 0.03%
154,500
– –
NUVB.WS
143
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$358K 0.01%
+134,028
New +$388K
ANNX icon
144
Annexon
ANNX
$883M
– –
-45,413
Closed -$1.14M
BFAM icon
145
Bright Horizons
BFAM
$3.81B
– –
-165,500
Closed -$28.6M
BIIB icon
146
CALL
Biogen
BIIB
$30.6B
– –
-130,000
Closed -$31.8M
CERT icon
147
Certara
CERT
$1.23B
– –
-150,000
Closed -$5.06M
CHRS icon
148
Coherus Oncology
CHRS
$192M
– –
-1,162,500
Closed -$20.2M
CNC icon
149
Centene
CNC
$32.9B
– –
-730,000
Closed -$43.8M
ELVN icon
150
Enliven Therapeutics
ELVN
$4.35B
– –
-90,125
Closed -$7.95M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.